Although thrombolysis is the most effective medical treatment for acute ischemic stroke, many stroke patients eligible for thrombolysis miss this treatment as a result of delay or refusal by the patients and/or their proxies. To explore the influences of prognostic information for different intervals from stroke onset to the start of thrombolytic treatment (OTT) and other factors on the prefere...

The number of cancer patients admitted to intensive care units (ICUs) around the world has increased with recent improvements in cancer therapies. Cancer is now recognized as a chronic disease that is associated with possible acute decompensation caused by cardiovascular, respiratory or infectious disorders, which makes treating these patients challenging. Pulmonary thromboembolism is a common ...

Therapy of acute ST-elevation myocardial infarction (STEMI) has undergone dramatic improvements during the past three decades, and in-hospital and 30-day mortality rates have tremendously decreased from .15–20% in the pre-thrombolytic area to 8–10% using fibrin-non-specific agents, to 6–8% using fibrin-specific thrombolytic agents, and down to 4.5% by the use of primary percutaneous coronary in...

BACKGROUND Acute massive pulmonary embolism (PE) carries an exceptionally high mortality rate. We explored how often adjunctive therapies, particularly thrombolysis and inferior vena caval (IVC) filter placement, were performed and how these therapies affected the clinical outcome of patients with massive PE. METHODS AND RESULTS Among 2392 patients with acute PE and known systolic arterial bl...

The ability of thrombolytic therapy to lower mortality in patients with acute myocardial infarction was first demonstrated in 1986 by the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. In the ensuing 10 years, large efforts have been undertaken to develop more effective and safer thrombolytic agents. In addition, the value of adjunctive agents influencing thrombotic...

Despite the fact that magnetic thrombolytic composites is an emerging area, all known so far systems are based on the similar mechanism of action: thrombolytic enzyme releases from the magnetic carrier leaving non-active matrix, thus making the whole system active only for a limited period of time. Such systems often have very complex structure organization and composition, consisting of materi...

OBJECTIVES We sought to determine trends in the treatment of myocardial infarction from 1990 through 1999 in the U.S. and to relate these trends to current guidelines. BACKGROUND Limited data are available to show how recent clinical trials and clinical guidelines have impacted treatment of myocardial infarction. METHODS Temporal trends in myocardial infarction treatment and outcome were as...

nagement of patients with thrombotic and thromboembolic complications during pre-, peri-, and postinterventional cardiologic procedures and acute thrombotic stroke, most often in combination with anticoagulants, antiplatelet agents or mechanical procedures, in order to achieve vascular reperfusion. Coronary Heart disease (CHD) is the most common cause of mortality not only in the United States ...

OBJECTIVE Deep venous thrombosis is a major health problem. Thrombolytic therapies are effective in recanalizing the veins and preventing post-thrombotic complications, but there is no consensus on selection criteria. The aim of this study was to investigate a fibrin-specific MRI contrast agent (EP-2104R) for the accurate quantification of thrombus' fibrin content in vivo and for the identifica...